利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.021 秒)

    Chimeric chikungunya virus and uses thereof
    1.
    发明授权
    Chimeric chikungunya virus and uses thereof 有权
    嵌合基孔肯雅病毒及其用途

    公开(公告)号：US08343506B2

    公开(公告)日：2013-01-01

    申请号：US12798796

    申请日：2010-04-12

    申请人： Ilya V. Frolov ,  Scott C. Weaver ,  Eryu Wang

    发明人： Ilya V. Frolov ,  Scott C. Weaver ,  Eryu Wang

    IPC分类号： A61K39/12 ,  C12N7/01 ,  C12N15/86 ,  C12Q1/70

    CPC分类号： C12N7/00 ,  A61K2039/5256 ,  C12N2770/36121

    摘要： The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays.

    摘要翻译： 本发明公开了包含异源甲病毒cDNA片段和基孔肯雅病毒cDNA片段的嵌合基孔肯雅病毒。 异源甲病毒可以包括但不限于辛德毕斯病毒，东马脑炎病毒或委内瑞兰马脑炎病毒。 本发明还公开了该嵌合基孔肯雅病毒作为疫苗和血清学和诊断测定法的用途。

    Chimeric chikungunya virus and uses thereof
    2.
    发明申请
    Chimeric chikungunya virus and uses thereof 有权
    嵌合基孔肯雅病毒及其用途

    公开(公告)号：US20110171249A1

    公开(公告)日：2011-07-14

    申请号：US12798796

    申请日：2010-04-12

    申请人： Ilya V. Frolov ,  Scott C. Weaver ,  Eryu Wang

    发明人： Ilya V. Frolov ,  Scott C. Weaver ,  Eryu Wang

    IPC分类号： A61K39/12 ,  C07H21/04 ,  C12N7/04 ,  C12Q1/70 ,  A61P37/04 ,  A61P31/14

    CPC分类号： C12N7/00 ,  A61K2039/5256 ,  C12N2770/36121

    摘要： The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays.

    摘要翻译： 本发明公开了包含异源甲病毒cDNA片段和基孔肯雅病毒cDNA片段的嵌合基孔肯雅病毒。 异源甲病毒可以包括但不限于辛德毕斯病毒，东马脑炎病毒或委内瑞兰马脑炎病毒。 本发明还公开了该嵌合基孔肯雅病毒作为疫苗和血清学和诊断测定法的用途。

    Attenuation of encephalitogenic alphavirus and uses thereof
    4.
    发明授权
    Attenuation of encephalitogenic alphavirus and uses thereof 有权
    脑炎病毒的减毒及其用途

    公开(公告)号：US08614082B2

    公开(公告)日：2013-12-24

    申请号：US13284098

    申请日：2011-10-28

    申请人： Ilya V. Frolov ,  Elena Frolova ,  Scott C. Weaver

    发明人： Ilya V. Frolov ,  Elena Frolova ,  Scott C. Weaver

    IPC分类号： C12N7/04 ,  A61K39/12

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5254 ,  C07K14/005 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36161

    摘要： The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, CVEE30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of CVEE, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of CVEE by its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.

    摘要翻译： 本发明被用于产生减毒和较少细胞病变形式的新世界甲病毒，其可用于免疫原性组合物中作为针对旧世界和新世界甲病毒的疫苗。 在这方面，本发明公开了VEEV，EEEV和最有可能的WEEV衣壳蛋白的N末端〜35-aa长肽在细胞转录的下调和细胞病变效应的发展中起着最关键的作用 。 鉴定的VEEV特异性肽CVEE30-68包括具有显着功能的两个结构域。 两个结构域的完整性不仅决定了CVEE的细胞内分布，而且对抑制转录的直接衣壳功能也是至关重要的。 VEEV TC-83基因组中由其特定于SINV特异的对应物替代CVEE的N-末端片段不影响体外病毒复制，但使体内细胞致病性降低并减弱。

    Attenuation of encephalitogenic alphavirus and uses thereof
    6.
    发明申请
    Attenuation of encephalitogenic alphavirus and uses thereof 审中-公开
    脑炎病毒的减毒及其用途

    公开(公告)号：US20100015179A1

    公开(公告)日：2010-01-21

    申请号：US12228710

    申请日：2008-08-15

    申请人： Ilya V. Frolov ,  Elena Frolova ,  Scott C. Weaver

    发明人： Ilya V. Frolov ,  Elena Frolova ,  Scott C. Weaver

    IPC分类号： A61K39/12 ,  C12N7/04 ,  A61P31/12

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5254 ,  C07K14/005 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36161

    摘要： The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, CVEE30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of CVEE, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of CVEE by its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.

    摘要翻译： 本发明被用于产生减毒和较少细胞病变形式的新世界甲病毒，其可用于免疫原性组合物中作为针对旧世界和新世界甲病毒的疫苗。 在这方面，本发明公开了VEEV，EEEV和最有可能的WEEV衣壳蛋白的N末端〜35-aa长肽在细胞转录的下调和细胞病变效应的发展中起着最关键的作用 。 鉴定的VEEV特异性肽CVEE30-68包括具有显着功能的两个结构域。 两个结构域的完整性不仅决定了CVEE的细胞内分布，而且对抑制转录的直接衣壳功能也是至关重要的。 VEEV TC-83基因组中由其特定于SINV特异的对应物替代CVEE的N-末端片段不影响体外病毒复制，但使体内细胞致病性降低并减弱。

    Attenuation of Encephalitogenic Alphavirus and Uses Thereof
    7.
    发明申请
    Attenuation of Encephalitogenic Alphavirus and Uses Thereof 有权
    脑炎病毒的衰减及其用途

    公开(公告)号：US20120100181A1

    公开(公告)日：2012-04-26

    申请号：US13284098

    申请日：2011-10-28

    申请人： Ilya V. Frolov ,  Elena Frolova ,  Scott C. Weaver

    发明人： Ilya V. Frolov ,  Elena Frolova ,  Scott C. Weaver

    IPC分类号： A61K39/12 ,  A61P37/04 ,  A61P31/14 ,  C12N7/04

    CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K2039/5254 ,  C07K14/005 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36161

    摘要： The present invention is drawn to generating attenuated and less cytopathic forms of New World alphaviruses that can be used in immunogenic compositions as vaccines against both Old and New World alphaviruses. In this regard, the present invention discloses that the N-terminal, ˜35-aa-long peptide of VEEV, EEEV and, most likely, of WEEV capsid proteins plays the most critical role in the downregulation of cellular transcription and development of cytopathic effect. The identified, VEEV-specific peptide, CVEE30-68, includes two domains with distinguished functions. The integrity of both domains determines not only the intracellular distribution of CVEE, but is also essential for direct capsid function in the inhibition of transcription. The replacement of the N-terminal fragment of CVEE by its SINV-specific counterpart in VEEV TC-83 genome does not affect virus replication in vitro, but makes it less cytopathic and more attenuated in vivo.

    摘要翻译： 本发明被用于产生减毒和较少细胞病变形式的新世界甲病毒，其可用于免疫原性组合物中作为针对旧世界和新世界甲病毒的疫苗。 在这方面，本发明公开了VEEV，EEEV和最有可能的WEEV衣壳蛋白的N-末端，〜35-aa长肽在细胞转录的下调和细胞病变效应的发展中起着最关键的作用 。 鉴定的VEEV特异性肽CVEE30-68包括具有显着功能的两个结构域。 两个结构域的完整性不仅决定了CVEE的细胞内分布，而且对抑制转录的直接衣壳功能也是至关重要的。 VEEV TC-83基因组中由其特定于SINV特异的对应物替代CVEE的N-末端片段不影响体外病毒复制，但使体内细胞致病性降低并减弱。